Evidence map›Paper›PMID 40712754›Full record

ArticleNeuropharmacology2025

Adenosine A

Mariana Alves, Rogério Gerbatin, Rebecca Kalmeijer, Denise Fedele, Tobias Engel, Detlev Boison

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mariana AlvesDepartment of Neurosurgery, Rutgers Robert Wood Johnson Medical School, New Jersey, USA; Royal College of Surgeons in Ireland, Dublin, Ireland.
Rogério GerbatinDepartment of Neurosurgery, Rutgers Robert Wood Johnson Medical School, New Jersey, USA.
Rebecca KalmeijerDepartment of Neurosurgery, Rutgers Robert Wood Johnson Medical School, New Jersey, USA.
Denise FedeleDepartment of Neurosurgery, Rutgers Robert Wood Johnson Medical School, New Jersey, USA.
Tobias EngelRoyal College of Surgeons in Ireland, Dublin, Ireland; FutureNeuro Research Ireland Centre or Chronic and Rare Neurological Diseases, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Detlev BoisonDepartment of Neurosurgery, Rutgers Robert Wood Johnson Medical School, New Jersey, USA; Brain Health Institute, Rutgers University, New Jersey, USA; Rutgers Cancer Institute, Rutgers University, New Jersey, USA. Electronic address: detlev.boison@rutgers.edu.

Funding

Therapies for Epilepsy Prevention - Focus on AdenosineR01NS127846 · NINDS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Detlev Boison · 2022 to 2026
$2.1M
NINDS NIH HHS R01 NS127846
6 · The paper itself

Abstract

Traumatic brain injury (TBI) is a leading cause of acquired epilepsy, with post-traumatic epilepsy (PTE) significantly contributing to morbidity and mortality. To date, there is no treatment capable to prevent the development of PTE, which remains an urgent unmet need. Previous studies suggest that adenosine A

Indexed as

BrainBrain Injuries, TraumaticCeftriaxoneExcitatory Amino Acid Transporter 2Receptor, Adenosine A2AAdenosine A2 Receptor AntagonistsAnimalsDisease Models, AnimalDrug SynergismEpilepsy, Post-TraumaticMaleMiceMice, Inbred C57BLPurinesSeizuresAdenosine A2 Receptor AntagonistsCeftriaxoneExcitatory Amino Acid Transporter 2istradefyllinePurinesReceptor, Adenosine A2ASlc1a2 protein, mouseA(2A)RControlled cortical injuryGlutamate transporter 1InflammationKainic acidPentylenetetrazoleSeizuresTraumatic brain injury

Identifiers

PMID40712754
PMCPMC12348367

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.